Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety & efficacy of Retatrutide, a first-in-class GIP, GLP-1 & glucagon triple hormone receptor agonist, in adults with obesity or overweight & knee osteoarthritis
Moreover, users who have already experienced a hypersensitivity reaction to tirzepatide, have gallbladder disease, or suffer from diabetic retinopathy should avoid tirzepatide
Chronic wounds show reduced microbial diversity, sustaining inflammation and increasing susceptibility to infection
In the Notes to Pharmacy section, a provider may write, d/c amlodipine. This means amlodipine is to be discontinued
Patients with Metformin intolerance who cannot achieve therapeutic doses represent a specific population that might benefit from Retatrutide as primary therapy
Conclusions and perspectives Mast cell activation is implicated in neuroinflammation, brain injuries, and various stress conditions